24 November - 27 November Milan
![]() |
![]() |
![]() |
![]() |
6-P | Clinical performance of -2 pro-prostate-specific antigen and Prostate Health Index for prediction of prostate cancer in a cohort of Spanish men | Angeles Sanchis-Bonet | ![]() |
![]() |
|||
7-P | Prostate cancer risk in relation to Insulin-like Growth Factor-1, IGF-Binding Protein-3 and Body Mass Index | Angeles Sanchis-Bonet | ![]() |
![]() |
|||
8-P | What the urologist needs to know | Adalgisa Guerra | ![]() |
![]() |
|||
16-P | Image guided radiotherapy with fiducial markers and intensity modulated radiotherapy in prostate cancer. Long terms outcomes | Carmen Salas | ![]() |
![]() |
|||
17-P | Implementation and effects of three Dutch decision aids for prostate cancer: Results from the JIPPA study | Julia van Tol-Geerdink | ![]() |
![]() |
|||
22-P | Laparoscopic salvage lymph node dissection in biochemical recurrence after radical prostatectomy and salvage radiotherapy. Feasibility, security, and results | Teresa Renedo Villar | ![]() |
![]() |
|||
24-P | Implantations of fiducials gold markers in the prostate for Image Guided Radiotherapy. Experience of a university hospital | Carmen Salas | ![]() |
![]() |
|||
61-P | Circulating tumor cells as liquid biopsies of prostate cancer bone metastases | Karin Welén | ![]() |
![]() |
|||
67-P | Stereotactic body radiotherapy for nodal oligorecurrent prostate cancer: A multi-institutional analysis | Piet Ost | ![]() |
![]() |
|||
77-P | Real-world outcomes of enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: A retrospective, multicenter study in Korea | Minyong Kang | ![]() |
![]() |
|||
78-P | Is there still a place for docetaxel rechallenge in metastatic castrate resistant prostate cancer? | Rodica Anghel | ![]() |
![]() |
|||
86-P | Impact of new therapies in the treatment of metastatic Castration Resistant Prostate Cancer (CPRCm): Retrospective analysis in a single institution in 2005-2015 | Olatz Etxaniz Ulazia | ![]() |
![]() |
|||
87-P | Docetaxel chemotherapy in hormone-sensitive prostate cancer: A single-institution experience | Mario Uccello | ![]() |
![]() |
|||
88-P | Laparoscopic salvage lymphadenectomy in patients treated with biochemical recurrence after radical prostatectomy after initially extended LND: Safety and objective response rate | Sergey Reva | ![]() |
![]() |
|||
89-P | Salvage high-dose-rate brachytherapy for macroscopic local recurrence after radical prostatectomy | David Buchser | ![]() |
![]() |
|||
98-P | Availability of prostate cancer rehabilitation resources and practice patterns: Results of a national survey | Piet Ost | ![]() |
![]() |
|||
100-P | Urachal carcinoma: A retrospective analysis of a reference cancer center | Ins Guerreiro | ![]() |
![]() |
|||
121-P | Baseline clinicopathological features as predictive markers of efficacy of Neoadjuvant Chemotherapy (NAC) in Muscle-Invasive Bladder Cancer (MIBC) | Albert Font Pous | ![]() |
![]() |
|||
124-P | Preoperative neutrophil to lymphocyte ratio as a predictor marker of adverse outcomes in patients undergoing radical cystectomy due to bladder cancer | Ariadna Fabià Mayans | ![]() |
![]() |
|||
135-P | The prognostic role of tissue TIMP-2 expression in patients with renal cell carcinoma | Pastora Beardo-Villar | ![]() |
![]() |
|||
137-P | Long-term response to mTOR inhibitors (everolimus) in mRCC patients: Single institution experience | Joanna Huszno | ![]() |
![]() |
|||
139-P | Comparison of sunitinib versus temsirolimus in patients with poor risk metastatic renal cell carcinoma | David Sarid | ![]() |
![]() |
|||
140-P | Outcome of octogenarian versus young patients with metastatic renal cell carcinoma, treated with sunitinib | David Sarid | ![]() |
![]() |
|||
146-P | Preoperative lipiodol marking improved safety and success rate on CT-guided cryoablation for small renal masses | Fumiya Hongo | ![]() |
![]() |
|||
149-P | Impact of precise quantitative assessment of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy | Ryuichi Mizuno | ![]() |
![]() |
|||
155-P | A double rare testicular cancer: Burned out tumor with vena cava thrombus presentation | Pedro Oliveira | ![]() |
![]() |
24 November - 27 November Milan
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|